Abstract
In the LAPTOP trial, combination therapy with once-daily insulin glargine + oral antidiabetic agents glimepiride and metformin (BOT) was compared to twice-daily premixed insulin (CT). BOT was safer and more effective than CT. Cost analysis of both regimens were compared over a 1-year period. Analyses were performed from the perspective of the German statutory health insurance. Costs per patient per year were on average €236 lower for BOT than for CT therapy. Economic advantage for BOT was robust to variation of expenses within a range of at least ±20%. Insulin utilisation and prices were the major cost drivers, followed by costs associated with monitoring of blood glucose levels. Cost analysis of the LAPTOP trial suggest that BOT is more cost effective alternative to CT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Janka, H.U., Plewe, G., Riddle, M.C., Kliebe-Frisch, C., Schweitzer, M.A., Yki-Järvinen H.: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28, 254–259 (2005)
Lauer-Taxe (official German price list for all registered drugs), Lauer-Fischer GmbH, Gebhardtstrasse 37–45, 90762 Fürth, www.lauer-fischer.de
Florian Müller GmbH—the friendly mail-order for diabetics, Wichmannstrasse 4, 22607 Hamburg, www.florian-mueller.de
Ypsomed GmbH, Otto-Volger Strasse 7c, 65843 Sulzbach/Taunus, www.ypsomed.de
Hoegy, B., Janka, H.U., Huppertz, E.: Economic evaluation of the LAPTOP-study results. Value Health 8(6), A 164 (2005)
Acknowledgements
The study was sponsored by Sanofi-Aventis Deutschland GmbH. The authors would like to thank Franz-Werner Dippel for his assistance in preparing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Janka, H.U., Högy, B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. Eur J Health Econ 9, 165–170 (2008). https://doi.org/10.1007/s10198-007-0057-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-007-0057-2